Skip to main content
Fig. 3 | Journal of Clinical Movement Disorders

Fig. 3

From: Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease

Fig. 3

Risk difference for specific adverse events. The risk differences for specific adverse events, including insomnia, drowsiness/somnolence, depression, akathisia, depression/agitated depression, parkinsonism, agitation, anxiety, vomiting, nausea, fall, fatigue, vomiting, upper respiratory infection, purpura, diarrhea, and coughing were assessed. Negative risk difference favors deutetrabenazine. The figure presents unadjusted data, in addition to data adjusted by baseline characteristics (TMC, TFC, and/or age). *p < 0.05. p-values comparing the risk differences between deutetrabenazine and tetrabenazine were obtained from z-tests. TFC = total functional capacity, TMC = total maximal chorea

Back to article page